Stockscreener 앱 받기
8.195
0.09%
-0.035
전일 마감가:
$8.23
열려 있는:
$8.21
하루 거래량:
195.42K
Relative Volume:
0.05
시가총액:
$1.80B
수익:
$52.04M
순이익/손실:
$-290.50M
주가수익비율:
-7.7289
EPS:
-1.0603
순현금흐름:
$-216.89M
1주 성능:
+2.91%
1개월 성능:
-13.35%
6개월 성능:
-32.27%
1년 성능:
+12.64%
1일 변동 폭
$8.16
$8.33
1주일 범위
$7.86
$8.36
52주 변동 폭
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.205 | 1.80B | 52.04M | -290.50M | -216.89M | -1.0603 |
VRTX
Vertex Pharmaceuticals Inc
|
435.62 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
640.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.86 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.89 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.09 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-15 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Q3 2025 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus
Q2 2025 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus
Ocular Therapeutix Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Selling Ocular Therapeutix Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Moomoo
Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions? - simplywall.st
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - The Globe and Mail
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - The Motley Fool
Why (OCUL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
[SCHEDULE 13G/A] OCULAR THERAPEUTIX, INC Amended Passive Investment Disclosure - Stock Titan
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New HR boss at Ocular Therapeutix lands 75,000 stock options, 25,000 RSUs - Stock Titan
Dole posts downbeat Q1 earnings, joins Ocular Therapeutix and other big stocks moving lower in Monday's pre-market session - MSN
Neuropathic Ocular Pain Therapeutics Market Size (7MM) - openPR.com
Ocular Therapeutix, Inc. $OCUL Shares Bought by Empire Life Investments Inc. - MarketBeat
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's P - Benzinga
Ocular Therapeutix prices $475M stock offering - MSN
Ocular Therapeutix outlines SOL-R top line data in Q1 2027 while advancing AXPAXLI NDA plan - MSN
Ocular Therapeutix reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Ocular Therapeutix reports inducement grants under Nasdaq listing rule 5635(C)(4) - TradingView
Twelve new Ocular employees get stock awards tied to 169,200 shares - Stock Titan
Ocular Therapeutix Price Target Maintained With a $18.00/Share by Needham - Moomoo
Ocular Therapeutix Starts SOL-X Trial As AXPAXLI Data And Valuation Diverge - Yahoo Finance
Ocular: SOL-1 Success Is Real, But Adoption Risks Keep Me At Hold (NASDAQ:OCUL) - Seeking Alpha
Number of shareholders of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Number of shareholders of Ocular Therapeutix Inc – BX:0OT - TradingView
Ocular Therapeutix Releases 2026 First Quarter Revenue Results - VisionMonday.com
Understanding Momentum Shifts in (OCUL) - Stock Traders Daily
A Quick Look at Today's Ratings for Ocular Therapeutix(OCUL.US), With a Forecast Between $18 to $30 - Moomoo
MSN Money - MSN
Assessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Expectations Meet Volatile Returns - Yahoo Finance
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks - TipRanks
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss By Investing.com - Investing.com India
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c) - TipRanks
Ocular Therapeutix Q1 Earnings Call Highlights - Yahoo Finance
Ocular Therapeutix Q1 2026 earnings preview - MSN
Why Ocular Therapeutix (OCUL) Stock Is Nosediving - TradingView
Ocular Therapeutix Q1 2026 Earnings Call Transcript - MarketBeat
OCUL: AXPAXLI's phase III success in wet AMD drives NDA plans and commercial readiness, backed by strong cash reserves - TradingView
Ocular Therapeutix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ocular Therapeutix's Q1 Net Loss Widens, Revenue Rises - marketscreener.com
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss - Investing.com
Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips - ChartMill
Q1 2026 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus
OCULAR THERAPEUTIX ($OCUL) Releases Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (OCUL) Ocular Therapeutix Posts Q1 Loss $0.40 a Share, vs. FactSet Est of $0.31 Loss - marketscreener.com
Earnings Flash (OCUL) Ocular Therapeutix, Inc. Reports Q1 Revenue $10.8M, vs. FactSet Est of $12.7M - marketscreener.com
Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings - Yahoo Finance
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.25%
0.46%
자본화:
|
볼륨(24시간):